Abivax (AAVXF) Net Cash Flow (2024 - 2026)

Abivax has reported Net Cash Flow for 3 years, with the latest figure at -$58.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 38.87% year-over-year to -$58.5 million in Q1 2026; TTM through Mar 2026 was $440.0 billion, a 473.86% increase from a year earlier, with the FY2025 full-year figure at $440.0 billion, up 473.97% from the prior year.
• Net Cash Flow was -$58.5 million for Q1 2026 at Abivax, down from $439.5 billion in the prior quarter.
• The five-year high for Net Cash Flow was $439.5 billion in Q4 2025, with the low at -$117.6 billion in Q4 2024.
• Average Net Cash Flow over 3 years is $35.8 billion, with a median of -$42.1 million recorded in 2025.
• The largest YoY upside for Net Cash Flow was 1527.7% in 2025 against a maximum downside of 232.67% in 2025.
• Over 3 years, Net Cash Flow stood at -$117.6 billion in 2024, then soared by 473.76% to $439.5 billion in 2025, then sank by 100.01% to -$58.5 million in 2026.
• The last three Net Cash Flow figures came in at -$58.5 million (Q1 2026), $439.5 billion (Q4 2025), and $626.0 million (Q3 2025), per Business Quant data.